The Pharma Data

DECEMBER 19, 2020

Today’s ACIP recommendation follows the December 1, 2020 ACIP recommendation for a Phase 1a rollout in which the first priority for COVID-19 vaccines is given to healthcare personnel treating patients and residents in long-term care facilities. Department of Health and Human Services (HHS) for review and adoption.

Vaccine 52

Vaccine Long-Term Care Facilities FDA Licensing 52

The Pharma Data

SEPTEMBER 18, 2020

The Marburg facility is expected to start the production of mRNA formulation for a Covid-19 vaccine in the first half of 2021, pending regulatory authorization or approval.

Vaccine 52

Vaccine Long-Term Care Facilities Clinical Supply Laboratories 52

The Pharma Data

APRIL 14, 2021

government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19. who require oxygen therapy due to COVID-19, OR. who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.

Government 52

Government Hospitals Long-Term Care Facilities Treatment 52

The Pharma Data

FEBRUARY 1, 2021

million shots have now been administered in long-term care facilities, according to the U.S. 1.351 variant contains a key mutation that appears to allow the virus to elude the full power of antibody treatments and vaccines. “I’m optimistic, this is good.” ” As of Saturday, more than 3.5

Nurses 52

Nurses Vaccine Long-Term Care Facilities Virus 52

The Pharma Data

OCTOBER 28, 2020

government to meet Operation Warp Speed goals – are fundamental to enable the most widespread and equitable access to our potential therapy,” said David A. government has committed that patients will have no out-of-pocket costs for the medicine, although healthcare facilities may charge a fee for the product’s administration.

Government 40

Government Long-Term Care Facilities Hospitals Therapies 40

The Pharma Data

JUNE 25, 2021

AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus.

Trials 52

Trials Virus Long-Term Care Facilities Government 52

The Pharma Data

NOVEMBER 9, 2020

. “The BLAZE-1 data show bamlanivimab, when given early in the disease course, may help patients clear the virus and reduce COVID-related hospitalizations, supporting our belief that neutralizing antibodies can be an important therapeutic option for patients fighting this virus,” said Daniel Skovronsky, M.D.,

Treatment 52

Treatment FDA Hospitals Long-Term Care Facilities 52